Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN · IEX Real-Time Price · USD
1.12
-0.03 (-2.61%)
At close: Dec 5, 2022 4:00 PM
1.11
-0.01 (-0.89%)
After-hours: Dec 5, 2022 4:42 PM EST
-2.61%
Market Cap 110.88M
Revenue (ttm) n/a
Net Income (ttm) -13.08M
Shares Out 97.48M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 111,213
Open 1.14
Previous Close 1.15
Day's Range 1.11 - 1.19
52-Week Range 0.8 - 3.16
Beta n/a
Analysts Buy
Price Target 7.40 (+560.7%)
Earnings Date n/a

About ALZN

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, whic... [Read more]

Industry Biotechnology
IPO Date Jun 15, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ALZN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ALZN stock is "Buy." The 12-month stock price forecast is 7.4, which is an increase of 560.71% from the latest price.

Price Target
$7.4
(560.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

LAS VEGAS--( BUSINESS WIRE )--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced that the Company is considering undertaking an exc...

1 week ago - Business Wire

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issue...

1 week ago - Accesswire

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months ...

LAS VEGAS--( BUSINESS WIRE )--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), reported its financial results for the third quarter ended Septemb...

Other symbols: NILE
1 week ago - Business Wire

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial...

LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today announced that Alzamend Neuro, Inc. (Nasdaq: AL...

Other symbols: NILE
1 month ago - Business Wire

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

2 months ago - Business Wire

6 Penny Stocks With 1,000% Upside Potential

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on Inve...

Other symbols: AGTCAMPEBRDSCRISDRRX
4 months ago - InvestorPlace

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine ...

11 months ago - Benzinga

Why Alzamend Neuro Stock Soared Today

The company hopes to advance the standard of care for people with dementia.

11 months ago - The Motley Fool

ALZN Stock Alert: What Is Going on With Alzamend Neuro Today?

ALZN stock has been on the move higher in anticipation that Alzamend Neuro will soon share the results from one of its key medication studies. The post ALZN Stock Alert: What Is Going on With Alzamend N...

11 months ago - InvestorPlace

ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?

Today, investors in preclinical biotech company Alzamend Neuro and ALZN stock are seeing impressive gains of more than 25% currently. The post ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?

1 year ago - InvestorPlace

See Why Alzamend Neuro Stock Is Rallying On Thursday

Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path f...

1 year ago - Benzinga

ALZN Stock: The Alzheimer's Clinical Trial News That Has Alzamend Neuro Soaring Today

Alzamend Neuro (ALZN) stock is on the move Thursday after getting an update from the U.S. Food and Drug Administration (FDA). The post ALZN Stock: The Alzheimer's Clinical Trial News That Has Alzamend N...

1 year ago - InvestorPlace

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA pro...

1 year ago - Benzinga

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #2nd_Treatment_to_Clinic--Alzamend Neuro Gets Positive FDA Pre-IND Response for AL002, a Therapeutic Vaccine that Seeks to Restore Patient's Immuno System to Comba...

1 year ago - Business Wire

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzhei...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group

1 year ago - Business Wire

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers

1 year ago - Business Wire

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the A...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's

1 year ago - Business Wire

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug ...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease

1 year ago - Business Wire

Why Alzamend Neuro Stock Fell More Than 14% Today

Investors have been driving it lower for over a month now, but the stock just reached a curious price level.

1 year ago - The Motley Fool

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

There's never been a better time to be a mouse with Alzheimer's disease.

1 year ago - The Motley Fool

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease.  Charles River Laboratories conducted t...

1 year ago - Benzinga

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzhei...

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model

1 year ago - Business Wire

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone

1 year ago - Business Wire

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1 s...

1 year ago - Benzinga

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits IND Application to the FDA for AL001, a lithium-based ionic cocrystal oral therapy for Dementia Related to Alzheimer's Disease

1 year ago - Business Wire